Core Insights - NRx Pharmaceuticals ended 2025 with $7.8 million in cash, eliminated all convertible debt, and expects to fund operations through at least the end of 2026 based on growing clinic revenues and ATM activity [1][4][23] - The company is pursuing three potential drug approvals while expanding its HOPE Therapeutics clinic network, which is already generating EBITDA-positive revenue [2][3] - NRx is advancing regulatory pathways for preservative-free ketamine and an investigational ketamine product, alongside an expanded strategy for its NRX-101 program [3][4] Financial Performance - NRx reduced its operating loss by approximately $2.3 million to $16.2 million for the year ended December 31, 2025, compared to $18.5 million in 2024, primarily due to lower R&D spending [22] - R&D expenses fell to $3.8 million from $6.2 million, driven by reduced clinical trial and development costs [22] - General and administrative expenses declined to $13.1 million, attributed to ongoing cost reduction initiatives [22] Drug Development and Approvals - NRx is pursuing an NDA for NRX-100 using clinical and real-world evidence, with a potential PDUFA decision by the end of 2026 or early 2027 [5][12][15] - The ANDA for KETAFREE is under FDA review, with a preliminary determination of bioequivalence to Ketalar and a targeted approval in summer 2026 [6][7][8] - The company has manufactured three registration batches of KETAFREE and anticipates having 200,000 units in inventory at the time of approval [9][8] HOPE Therapeutics and Clinic Expansion - HOPE Therapeutics clinics are generating revenue and helping to lower cash burn, with plans to open additional clinics in West Palm Beach, Sarasota, Boston, and Denver [4][20][21] - The subsidiary began generating revenue after acquiring Dura Medical and later added Cohen & Associates, which is described as revenue-generating and EBITDA positive [20] - NRx has launched a nationwide expanded access program for D-cycloserine in conjunction with TMS treatment, awaiting a confirmatory Phase III trial [19][20] Strategic Partnerships and Innovations - NRx appointed Dr. Joshua C. Brown as Chief Medical Innovation Officer to lead initiatives related to neuroplastic care [19] - The company is pursuing a patentable sustained release form of D-cycloserine to enhance TMS treatment [18] - NRx has partnered with neurocare group AG for the Apollo TMS device, which is installed at over 400 U.S. clinical locations [21]